



Universiteit
Leiden
The Netherlands

Optimization of sunitinib treatment in metastatic renal cell carcinoma : pharmacogenetic evidence and challenges

Liu, X.

Citation

Liu, X. (2018, May 15). *Optimization of sunitinib treatment in metastatic renal cell carcinoma : pharmacogenetic evidence and challenges*. Retrieved from <https://hdl.handle.net/1887/62361>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/62361>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/62361> holds various files of this Leiden University dissertation

Author: Liu, Xiaoyan

Title: Optimization of sunitinib treatment in metastatic renal cell carcinoma :
pharmacogenetic evidence and challenges

Date: 2018-05-15

**Optimization of sunitinib treatment in
metastatic renal cell carcinoma
pharmacogenetic evidence and challenges**

Xiaoyan Liu

The research presented in this thesis was performed at the Department of Clinical Pharmacy and Toxicology of Leiden University Medical Center, The Netherlands.

Publication of this thesis was financially supported by Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center

Cover design Xiaoyan Liu
Lay out Xiaoyan Liu
Printed by Ridderprint BV
ISBN: 978-94-92026-14-9

Copyright © 2018 Xiaoyan Liu

All rights reserved. No part of this publication may be reproduced, stored in retrieval system or transmitted in any form or by any means, electronically, mechanically, by photocopying, recording or otherwise, without prior written permission of the author.

**Optimization of sunitinib treatment in
metastatic renal cell carcinoma
pharmacogenetic evidence and challenges**

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op dinsdag 15 mei 2018
klokke 11:15 uur

door

Xiaoyan Liu

geboren te Longkou, P.R. China

in 1983

PROMOTIECOMMISSIE

Promotor

Prof. dr. H.-J. Guchelaar

Copromotor

Dr. J. J. Swen

“Love the life you live. Live the life you love.”

— Bob Marley

CONTENTS

Chapter 1	General introduction and outline	9
Chapter 2	Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis <i>Acta Oncologica. 2017 Apr;56(4):582-589</i>	21
Chapter 3	Association of single nucleotide polymorphisms in <i>IL8</i> and <i>IL13</i> with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma <i>Eur J Clin Pharmacol. 2015 Dec;71(12):1477-84</i>	49
Chapter 4	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients <i>Oncotarget. 2017 Jan 3;8(1):1204-1212</i>	71
Chapter 5	Effect of <i>CYP3A4</i> rs4646437 on clearance of sunitinib and its active metabolite SU12662 <i>Manuscript in preparation</i>	89
Chapter 6	<i>CYP3A5</i> rs776746, rather than <i>CYP3A4</i> rs4646437, is the causal <i>CYP3A</i> variant in the association with sunitinib-induced hypertension <i>Submitted</i>	103
Chapter 7	A genetic polymorphism in <i>CTLA-4</i> is associated with overall survival of sunitinib-treated patients with clear cell metastatic renal cell carcinoma <i>Accepted by Clin Cancer Res</i>	115
Chapter 8	What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality? <i>Pharmacogenomics. 2017 Jan;18(1):1-4</i>	141
Chapter 9	General discussion and future perspectives	149
Chapter 10	Summary	169
	Nederlandse samenvatting	173
	全文总结 (Summary in Chinese)	177
	List of publications	181
	Curriculum Vitae	183
	Acknowledgements	185

